Making Medicine Incubate Coalition

The price control policies that are being discussed in Congress have the potential to harm innovation in the life science industry. But how, exactly?
In this episode, we interview Kirsten Axelsen, Senior Advisor at Charles Rivers Associates , about what would change in biopharma if price controls were implemented.
In this episode, we discuss:

The close relationship between economy and drug development
The U.S.’s role in developing over 40% of the world’s new medicines
The potential reduction of biopharma global revenues by 19%
What it means globally when 8-15 fewer medicines are made per decade
Some flaws in the health technology assessment (HTI) regarding clinical trials


As we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what’s top of mind, what story you want to hear, or what you find interesting!
To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.

What goes into a bottle of new medicine is more than the proverbial 15 years and $2 billion. It takes great science, certainly, but it also takes 15 years of relationships.
No one can make medicine alone, not even Big Pharma. Collaboration, innovation, and industry relationships are key to bringing life-saving medicine to market.
In this episode, I interview Imran Nasrullah, Vice President & Head, Open Innovation Center North America - East at Bayer Pharmaceuticals, about strengthening relationships within the biotech ecosystem.
In this episode we discuss:

The importance of industry relationships in making medicine
How relationships mitigate the challenge of drug development
Mentoring options for small, innovative companies
Relying on partners to actualize different paths to commercialization

As we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what’s top of mind, what story you want to hear, or what you find interesting!
To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.
Listening on a desktop & can’t see the links? Just search for Making Medicine in your favorite podcast player. 

High cost out-of-pocket drugs and obstacles to reduce those prices for patients plague the health industry. With patients in mind, organizations are looking to invest and bring drugs directly to market.
Gaurav Gupta and Hugo Beekman, Co-Founders of Ascendant BioCapital, join the show to discuss their organization and how they’re focusing on drugs that truly make a difference for patients.

What we talked about:

The Founding of Ascendant BioCapital
The Medical & Investing Backgrounds of the Founders
Impactful Experiences in the Industry
Testifying Before Congress & Issues with Out-Of-Pocket Costs
Importance of Intellectual Property to Biotech

To hear more interviews like this one, subscribe to the Making Medicine Podcast on Apple Podcasts, Spotify, or your preferred podcast platform.

As it turns out, many perceptions about the pharmaceutical industry are based without all of the facts.


That’s why we’re sitting down to understand the data with Ravi Mehrotra, Thought Leader and former Senior Managing Director of Biotechnology Equity Research at Evercore ISI.


What we talked about:
- Defining WBPI while taking a closer look at the industry
- The reality that winners pay for all the losers
- Risk and profitability
- HR3 legislation
- Wall Street’s position on the drug pricing debate


Check out these resources we mentioned during the podcast:
- HR 3 legislation


As we continue this new journey together, we would love to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what’s top of mind, what story you want to hear, or what you find interesting!


To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.

Intellectual property (IP) rights have been the driving force behind innovation and entrepreneurship. However, IP has more recently been seen in a negative light.


Through the COVID-19 Pandemic, vaccine IP rights have come into question: should IP rights be waived when concerning an essential technology?


Andrei Iancu, Former Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office, joins the podcast to discuss his views and concerns on IP rights:


What we talked about:
- The Benefits of IP
- How Sentiment of IP Has Changed
- Short, Medium, & Long Term Concerns to Waiving IP Rights
- Where Concerns Should Be Focused & How to Improve IP


Check out the resources below for more information:
- Andrei’s LinkedIn
- Our host: John Stanford’s LinkedIn
- www.incubatecoalition.com

To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.

The fight against Antimicrobial Resistance (AMR) is challenging due to financial, ethical, and legislative issues. Combating infectious disease can prove to be a risky financial investment but much less in comparison to the global impact if solutions are not researched.


Alfonso Chang is the Managing Director of Relativity Healthcare Partners; he shares insight into the challenges and how to overcome them:
- Investor Hesitancy

- Higher clinical and ethical implications

- Preference of existing therapies over new ones

- Unintended consequences from lawmakers due to drafted legislative language


Check out the resources below for more information:

- Alfonso’s LinkedIn

- Our host: John Stanford’s LinkedIn


To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.